FREE COMMUNICATION 32

14.15-16.00   G104-G105

 

Translational CKD research

 

Chairs: Gerjan Navis, Groningen, The Netherlands
             Giovanni Tripepi, Reggio Calabria, Italy
 
FREE COMMUNICATIONS
 

TO056
USING HUMAN PLURIPOTENT STEM CELLS TO MODEL KIDNEY DISEASE PATHOPHYSIOLOGY
AND THERAPY
Benjamin S. Freedman1,2, Albert Q Lam1,2, Jamie L. Sundsbak3, Ryuji Morizane1, Rossella Iatrino1, Xuefeng Su1, Sarah J. Koon3, Maoqing Wu1, Laurence Daheron2, Todd Valerius1,2, Peter C. Harris3, Jing Zhou1,2, Joseph V. Bonventre1,2 1Brigham and Women’s Hosp, Boston, MA; 2Harvard Stem Cell Inst, Cambridge, MA; 3Mayo Clinic, Rochester, MN
 
TO057
USING CHINESE HERBAL MEDICINE CONTAINING MU-TONG IS ASSOCIATED WITH UPPER
URINARY TRACT CANCER IN PATIENT WITH END-STAGE RENAL DISEASE
Shang-Jyh Hwang1, Ming-Yen Lin1, Huei-Lan Lee1, Hong-Long Lin1, Wei-Ming Li1, Wen-Jeng Wu1,
Chun-Hsiung Huang1, Li-Tzong Chen2 1Kaohsiung Medical Univ Hosp, Kaohsiung Medical Univ, Kaohsiung, Taiwan, 2National Inst Cancer Research, National Health Research Insts, Tainna, Taiwan

TO058
EARLY MORTALITY WAS HIGH AND WAS HIGHLY ASSOCIATED WITH FUNCTIONAL STATUS
(FS) IN THE INCIDENT JAPANESE HEMODIALYSIS PATIENTS, ESPECIALLY IN THE ELDERLY
Masahiko Yazawa1, Ryo Kido2, Kenjiro Kimura1, Seiji Ohira3, Takeshi Hasegawa4, Norio Hanafusa4,
Kunitoshi Iseki4, Yoshiharu Tsubakihara4, Yugo Shibagaki1
1St Marianna Univ School of Medicine, Kanagawa, Japan, 2Inagi Municipal Hosp, Tokyo, Japan, 3Sapporo Kita Clinic, Sapporo, Hokkaido, Japan, 4Committee Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan
 
TO059
HIGHER MORTALITY IN RURAL END STAGE KIDNEY DISEASE PATIENTS IN AUSTRALIA
Sradha Kotwal1, Angela Webster2, Alan Cass3, Martin Gallagher4,1
1George Inst Global Health, Sydney, Australia, 2Sydney School of Public Health, Sydney, Australia,
3Menzies School of Health Research, Darwin, Australia, 4Concord Clinical School, Sydney, Australia
 
TO060
ASSOCIATION OF SERUM AND DIALYSATE SODIUM AND SODIUM GRADIENT WITH MORTALITY
IN INCIDENT HEMODIALYSIS PATIENTS: RESULTS FROM THE INTERNATIONAL MONITORING
DIALYSIS OUTCOMES (MONDO) INITIATIVE
Jochen G. Raimann1, Len A. Usvyat2, Olynka Vega-Vega3,3, Lars Penne4, Jeroen Kooman5, Frank
Van Der Sande5, Stephan Thijssen1, Daniele Marcelli6, Bernard Canaud6, Nathan W. Levin1, Yuedong
Wang7, Peter Kotanko1, & The MONDO Initiative8
1Renal Research Inst, New York, NY; 2Fresenius Medical Care NA, Waltham, MA; 3National Inst Medical Sciences, Mexico City, Mexico, 4VU Univ Medical Center, Amsterdam, Netherlands, 5Maastricht Univ Medical Centre, Maastricht, Netherlands, 6Fresenius Medical Care, Bad Homburg, Germany, 7UC Santa Barbara, Santa Barbara, CA; 8MONDO Initiative, New York, NY
 
TO061
ASYMMETRIC DIMETHYLARGININE (ADMA) AMPLIFIES THE RISK BY BACKGROUND CARDIOVASCULAR
COMORBIDITIES IN DIALYSIS PATIENTS
Giovanni Tripepi1, Renke Maas2, Rainer Böger3, Carmine Zoccali1, Francesca Mallamaci1
1CNR-IFC, Reggio Calabria, Italy 2Inst Experimental and Clinical Pharmacology and Toxicology, Erlangen, Germany, 3Inst Clinical Pharmacology and Toxicology, Hamburg, Germany
   
back to the timetable